vai alle Pubblicazioni
Pubblicazioni antecedenti il 2004
pubblicazioni
1. Expression of an IGF-I
receptor dominant negative mutant induces apoptosis, inhibits
tumorigenesis and enhances chemosensitivity in Ewing's sarcoma
cells. K Scotlandi, S Avnet, S Benini, MC Manara, M Serra, V
Cerisano, S Perdichizzi, PL Lollini, C De Giovanni, L Landuzzi, P
Picci. Int J Cancer, 101:11-6, 2002.
2. The influence of alumina
and ultra-high molecular weight polyethylene particles on
osteoblast-osteoclast cooperation. D Granchi, G Ciapetti, I Amato,
S Pagani, E Cenni, LM Savarino, S Avnet, JL Peris, A
Pellacani, N Baldini, A Giunti. Biomaterial, 25:4037-45, 2004.
3. Isolation and
characterization of a new cell line from a renal carcinoma bone
metastasis. S Avnet , E Cenni, D Granchi, F Perut, I
Amato, L Battistelli, ML Brandi, A Giunti, N Baldini. Int J Cancer,
24:1705-11, 2004.
4. In vitro blockade of
receptor activator of nuclear factor-kappa B ligand prevents
osteoclastogenesis induced by neuroblastoma cells. D Granchi, I
Amato, L Battistelli, S Avnet, S Capaccioli, L Papucci, M
Donnini, A Pellacani, ML Brandi, A Giunti, and N Baldini. Int J
Cancer, 111:829-38, 2004.
5. Molecular basis of
osteoclastogenesis induced by osteoblasts exposed to wear
particles. D Granchi, I Amato, L Battistelli, G Ciapetti, S Pagani,
S Avnet, N Baldini , A Giunti. Biomaterials, 26:2371-9,
2005.
6. Ingegneria tissutale
dell'osso: strategie e modelli in vitro. G Ciapetti, S Pagani, S
Avnet, N Baldini. In Baldini N and Giunti A eds: Applicazioni
cliniche della ricerca ortopedica. I volume, CLUEB, Bologna, 99p,
2005.
7. Inhibition of
antiangiogenic activity of renal carcinoma by an antisense
oligonucleotide targeting fibroblast growth factor-2. E Cenni, F
Perut, M Zuntini, D Granchi, I Amato, S Avnet, ML Brandi, A
Giunti, N Baldini. Anticancer Res, 25:1109-13, 2005.
8. Primitive and bone
metastatic renal carcinoma cells promote osteoclastogenesis through
endothelial cells. E Cenni, F Perut, D Granchi, I Amato, S
Avnet, ML Brandi, A Giunti, N Baldini. Anticancer Res,
26:3065-9, 2005.
9. MET over-expression turns
human primary osteoblasts into osteosarcomas. S Patane', S
Avnet , N Coltella, B Costa , S Sponza, M Olivero, E Vigna, L
Naldini, N Baldini, R Ferracini, S Corso, S Giordano, PM Comoglio,
MF Di Renzo. Cancer Res, 66:4750-7, 2006.
10. Effects of antisense mediated inhibition of
cathepsin K on human osteoclasts obtained from peripheral blood.
S Avnet , A Lamolinara, N Zini, L Solimando, G
Quacquaruccio, NM Maraldi, A Giunti, N Baldini. J Orthop Res,
24:1699-1708, 2006.
11. Interferon-alpha inhibits in vitro osteoclast
differentiation and renal cell carcinoma-induced angiogenesis. S
Avnet, E Cenni, F Perut, D Granchi, ML Brandi, A Giunti, N.
Baldini. Int J Oncol, 30(2):469-476, 2007.
12. Inhibition of angiogenesis via FGF-2 blockage in
primitive and bone metastatic renal cell carcinoma. E Cenni E, F
Perut, D Granchi, S Avnet, I Amato, ML Brandi, A Giunti, N
Baldini. Anticancer Res, 27:315-9, 2007.
13. Sequence and TLR9 independent increase of TRACP
expression by antisense DNA and siRNA molecules. P Muhonen, S
Avnet, RN Parthasarathy, AJ Janckila, JM Halleen, T
Laitala-Leinonen, HK Vaananen. Biochem Biophys Res Commun,
359:889-95, 2007.
14. Biocompatibility of
poly(D,L-lactide-co-glycolide) nanoparticles conjugated with
alendronate. E Cenni, D Granchi, S Avnet, C Fotia, M
Salerno, D Micieli, MG Sarpietro, R Pignatello; F Castelli, N
Baldini. Biomaterials 29:1400-11, 2008.
15. Histogenetic Characterization of Giant Cell
Tumor of Bone. M Salerno, S Avnet M Alberghini, A
Giunti, N Baldini. Clin Orthop Rel Research, 466:2081-91, 2008.
16. Effects of prelamin A processing inhibitors on
the differentiation and activity of human osteoclasts. N. Zini, S
Avnet, S Ghisu, NM Maraldi, S Squarzoni, N Baldini, G Lattanti. J
Cell Biochem, 105:34-40, 2008.
17. Increased osteoclast activity is associated with
aggressiveness of osteosarcoma.. Avnet S , Longhi A, Salerno
M, Halleen JM, Perut F, Granchi D, Ferrari S, Bertoni F, Giunti A,
Baldini N. Int J Oncol. 2008 Dec;33(6):1231-8.
18. A novel biomaterial for osteotropic drug
nanocarriers: synthesis and biocompatibility evaluation of a
PLGA-ALE conjugate. Pignatello R, Cenni E, Micieli D, Fotia C,
Salerno M, Granchi D, Avnet S, Sarpietro MG, Castelli F,
Baldini N. Nanomed, 4:161-75, 2009.
19. Insulin receptor isoform A and insulin-like
growth factor II in human osteosarcoma. S Avnet , L Sciacca,
M Salerno, G Gancitano, F Cassarino, A Longhi, M Zakikhani, JM
Carboni, M Gottardis, M Pollak, R Vigneri, N Baldini. Cancer Res,
69:2443-52, 2009.
20. Yuasa K, Avnet S, Salerno M, Mori K,
Ishikawa H, Sudo A, Baldini N, Uchida A, Ito Y. Spontaneous
formation of multinucleated giant cells with bone resorbing
activity by long culture of human peripheral blood CD14-positive
monocytes in vitro. Cell Commun Adhes. 2010;17(1):13-22.
21. Savarino L, Avnet S, Greco M, Giunti A,
Baldini N. Potential role of tartrate-resistant acid phosphatase 5b
(TRACP 5b) as a surrogate marker of late loosening in patients with
total hip arthroplasty: a cohort study. J Orthop Res.
2010;28(7):887-92.
22. Cenni E, Avnet S, Fotia C, Salerno M,
Baldini N. Platelet-rich plasma impairs osteoclast generation from
human precursors of peripheral blood. J Orthop Res.
2010;28(6):792-7.
23. Cenni E, Savarino L, Perut F, Fotia C, Avnet
S, Sabbioni G. Background and rationale of platelet gel in
orthopaedic surgery. Chir Organi Mov. 2010;94(1):1-8.
24. Bone-targeted doxorubicin-loaded nanoparticles
as a tool for the treatment of skeletal metastases. Salerno M,
Cenni E, Fotia C, Avnet S, Granchi D, Castelli F, Micieli D,
Pignatello R, Capulli M, Rucci N, Angelucci A, Del Fattore A, Teti
A, Zini N, Giunti A, Baldini N. Curr Cancer Drug Targ
2010;10(7):649-59.
25. Osteoblasts from a Mandibuloacral dysplasia
patient induce human blood precursors to differentiate into active
osteoclasts. Avnet S, Pallotta R, Perut F, Baldini N, Pittis
MG, Saponari A, Lucarelli E, Dozza B, Greggi T,Maraldi NM, Capanni
C, Mattiolie E, Columbaro M, Lattanzi G. BBA-MOL BASIS DIS
(in press).
26. Insulin receptor isoforms modulate the behavior
of human osteoblasts. Avnet S, Perut F, Salerno M, Sciacca
L, Baldini N. Eur Cell and Mater (Sumbitted).
27. Neuroblastoma-derived IGF-2 induces osteoclast
differentiation via IGF1R. Avnet S, Salerno E, Quacquaruccio
G, Granchi D, Giunti A, Baldini N. Exp Cell Res (submitted).
Posters
1. Anchorage-independent growth and prolonged
survival of primary human osteoblasts over-expressing the MET
receptors by means of transduction with lentiviral vectors. S
Patanè, S Avnet, N Coltella, M Olivero, E Vigna, L Naldini, R
Ferraccini, N Baldini, MF Di Renzo. Tumori, Supplement 2 to Volume
87, Number 4, pp 31-32, 2001 (XVII Symposium of the Italian Cancer
Society - Naple, 2001)
2. Anchorage independent growth and prolonged
survival of primary human osteoblasts over-expressing the met
receptors by means of transduction with lentiviral vectors. N
Coltella, S Patane', S Avnet, M Olivero, E
Vigna, L Naldini, N Baldini, MF Di Renzo, R
Ferracini (CTOS Annual meeting 2001)
3. Anchorage independent survival of primary human
osteoblasts overexpressing Met receptor by means of transfection
via lentiviral vectors. N Baldini, S Avnet, L Naldini, S Patanè, M
Olivero, R Ferracini, N Coltella, A Giunti, MF Di Renzo, E Vigna
(48th Annual Meeting of the Orthopaedic Research Society - Dallas,
10-13 Feb 2002)
4. Cementi acrilici e modulazione della espressione
di osteoprotegerina e osteoprotegerina-ligand in cellule
osteoblast-like. D Granchi, E Cenni, L Savarino, G Ciapetti, S
Avnet, N Baldini, A Giunti (Italian Orthopaedic Research Society
meeting - Roma, 11 Nov 2001)
5. Neoplastic transformation of primary human
osteoblasts over-expressing the met receptor by means of
transduction with lentiviral vectors. R Ferracini, N Baldini, N
Coltella, S Avnet, S Patane', M Olivero, L Naldini, MF Di Renzo
(Connective Tissue Oncology Society Annual Meeting - San Francisco,
2002)
6. Molecular mechanisms of osteolysis in advanced
neuroblastoma. D Granchi, I Amato, L Battistelli, S Avnet, S
Capaccioli, ML Brandi, N Baldini. Tumori, Pag. 53, 2002 (XXIX
Simposio della societa' italiana di cancerologia “Dall'oncologia
molecolare alla terapia molecolare” - Genova, 27-30 Oct 2001)
7. The renal cell carcinoma cell line ACHN increases
bone endothelial cell proliferation and induces tubulogenesis in
vitro. D Perut, E Cenni , D Granchi, S Avnet, ML Brandi, N Baldini,
A Giunti. Tumori, Pag. 53, 2002 (XXIX Simposio della societa'
italiana di cancerologia “Dall'oncologia molecolare alla terapia
molecolare” - Genova, 27-30 Oct 2001)
8. Role of IGF-IR in metastatic osteolysis. S Avnet,
C Cavallo, D Granchi, ML Brandi, A Giunti, N Baldini. Tumori, Pag.
45, 2002 (XXIX Simposio della societa' italiana di cancerologia
“Dall'oncologia molecolare alla terapia molecolare” - Genova, 27-30
Oct 2001)
9. Pathogenesis of bone metastasis in advanced
neuroblastoma: role of Rank-l/Rank/OPG network. I Amato, D Granchi,
L Battistelli, S Avnet, S Capaccioli, ML Brandi, N Baldini. New
trends in cancer therapy, abstract book, pg 64, 2002 (New Trend in
Cancer Therapy - Rovigo, 3-6 Dic 2002)
10. Tossicità degli ioni metallici
in pazienti con artroprotesi d'anca. D Granchi, L Savarino, E
Cenni, G Ciapetti, M Greco, S Avnet, R Rotini, N Baldini, A Giunti
(Convegno Gruppo Italiano Biomateriali – VIII^ Giornata Società
Italiana Biomateriali “Le Aspettative Cliniche della Ricerca e
Sviluppo dei Biomateriali” - Bologna, 8-9 Nov 2002)
11. Effetto di concentrati
piastrinici attivati con trombina su osteoblasti umani. E Cenni, G
Ciapetti, D Granchi, L Savarino, S Pagani, F Perut, S Avnet, N
Baldini, A Giunti (Convegno Gruppo Italiano Biomateriali – VIII^
Giornata Società Italiana Biomateriali “Le Aspettative Cliniche
della Ricerca e Sviluppo dei Biomateriali” - Bologna, 8-9 Nov
2002)
12. Insulin-like growth factor
receptor: a new target for metastatic osteolysis. S Avnet, C
Cavallo, D Granchi, ML Brandi, A Giunti, N Baldini. New trends in
cancer therapy, abstract book, pg 65, 2002 (New Trend in Cancer
Therapy - Rovigo, 3-6 Dic 2002)
13. Endothelial cell proliferation
induced by the renal cell carcinoma cell line ACHN and osteoclast
activation. F Perut, E Cenni, D Granchi, S Avnet, I Amato, L
Battistelli, C Cavallo, ML Brandi, A Giunti, N Baldini. New trends
in cancer therapy, abstract book, pg 82, 2002 (New Trend in Cancer
Therapy - Rovigo, 3-6 Dic 2002)
14. Disorganization of actin-ring
in human osteoclasts with impaired cathepsin k expression. S Avnet,
A Lamolinara, D Granchi, A Giunti, N Baldini. Calcif Tissue Int
77:365, 2003 (30th European Symposium on Calcified Tissues - Roma,
8-12 May 2003)
15. Actin-ring derangements in
human osteoclasts by cathepsin K antisense oligonucleotide
treatment. S Avnet, A Lamolinara, A Giunti, and N Baldini. Bone.
Supplement to volume 32, numero 5, pag S160, 2003 (IBMS – JSBMR
International Bone and Mineral Society, Japan Bone and Mineral
Society – Osaka, 3-7 Jun 2003)
16. Effects of activated platelet
concentrates on the proliferation and specific functions of
bone-derived cells. E Cenni, G Ciapetti, D Granchi, L Savarino, F
Perut, S Pagani, S Avnet, D Dallari, ML Brandi, A Giunti, N
Baldini. Materialen, volume 4, numero 2, pag 95, 2003
(Internationales Symposium “Interface Biology of Implants”-
Rostock, 14-16 May 2003)
17. An in vitro model to
investigate the osteoblast-osteoclast interaction in presence of
wear debris. I Amato, G Ciapetti, D Granchi, L Battistelli, S
Pagani, E Cenni, LM Savarino, S Avnet, A Giunti, N Baldini. JABB
(Ischia (NA), 8-10 Sept 2003)
18. Renal cell carcinoma cells
induce endothelial cell proliferation and osteoclast activation. E
Cenni, F Perut, S Avnet, ML Brandi, A Giunti, N Baldini. I
supplementi di Tumori 3:42, 2003 (XLV Congresso Nazionale della
Società Italiana di Cancerologia – Bergamo, 9-12 Nov 2003)
19. In vitro effect of low doses
of interferon-alfa on human osteoclasts activity and
differentiation. S Avnet, G Quacquaruccio, A Lamolinara, A Giunti,
N Baldini. I supplementi di Tumori. 3:116, 2003 (XLV Congresso
Nazionale della Società Italiana di Cancerologia – Bergamo, 9-12
Nov 2003)
20. Cathepsin K antisense
inhibition of cell polarization and bone resorption in human
osteoclasts. S Avnet, A Lamolinara, N Zini, L Solimando, G
Quacquaruccio, NM Maraldi, N Baldini, A Giunti (VI Congresso
Nazionale IORS – Bologna, 23-24 Apr 2004)
21. Osteoclast activating ability
and antiangiogenic properties of renal carcinoma cell lines, both
primitive and bone metastatic. F Perut, E Cenni, S Avnet, ML
Brandi, N Baldini, A Giunti (VI Congresso Nazionale IORS – Bologna,
23-24 Apr 2004)
22. IGF-IR and osteoclast activity
in skeletal metastases of neuroblastoma. S Avnet, G Quacquaruccio,
A Lamolinara, D Granchi, A Pellacani, N Baldini, A Giunti. Calcif
Tissue Intern 74(Supp. 1):S109, 2004 (31st European Symposium on
Calcified Tissues – Nizza, 5-9 Jun 2004)
23. Role of IGF-IR in osteoclast
biology and differentiation. S Avnet, G Quacquaruccio, A
Lamolinara, D Granchi, A Giunti, N Baldini. J Bone Mineral Res 19
(Suppl. 1):S409, 2004 (26th Annual Meeting of the American Society
for Bone and Mineral Research – Seattle, 1-5 Oct 2004)
24. In vitro effects of an
antisense oligonucleotide targeting fgf-2 on renal carcinoma cells
metastasizing to bone. E Cenni, F Perut, M Zuntini, I Amato, S
Avnet, A Giunti, N Baldini (10th International congress of the
metaastasis research society “Progress against tumor progression” –
Genova, 17–20 Sept 2004, pp71)
25. Serum markers of loosening in
patients with THA. A Pellacani, S Avnet, L Savarino, D Granchi, M
Greco, M Calderoni, A Giunti, N Baldini (European Orthopaedic
Research Society Annual Meeting – Amsterdam, 25-27 Nov 2004)
26. Interferon-alpha as an
anti-osteolytic drug for the treatment of bone metastases of
renal cell carcinoma. S Avnet, E Cenni, G Gancitano, F Perut, D
Granchi, ML Brandi, A Giunti, N Baldini. Cancer treatment review
2005 31,S44 (Vith International Conference on Cancer induced bone
diseases (CIBD V) - Davos, Switzerland, 20–24 Mar, 2005)
27. Antisense strategies to
prevent osteoclastogenesis induced by neuroblastoma cells. I Amato,
D Granchi, S Avnet, M Donnini, L Papucci. Cancer treatment review
2005 31,S32 (Vith International Conference on Cancer induced bone
diseases (CIBD V) - Davos, Switzerland, 20-24 Mar, 2005)
28. Height and pathogenesis of
osteosarcoma. N Baldini, S Avnet, A Pellacani, A Pasini, A Longhi,
A Giunti. Cancer treatment review 2005 31,S44 (Vith International
Conference on Cancer induced bone diseases (CIBD V) - Davos,
Switzerland, 20-24 Mar, 2005)
29. Mesenchymal Stromal Cell
adhesion and proliferation on ion-irradiated and RGD-modified
polymer substrates. F Perut, M Salerno, S Pagani, V Devescovi, I
Amato, S Avnet, C Satriano, G Marletta, N Baldini (ESB2005
–Sorrento, 11-15 Sept 2005)
30. In vitro study of human
osteoclast activity on poly(e-caprolactone) as a bone substitute
biomaterial. S Avnet, G Ciapetti, D Martini, A Ruggeri, A Giunti, C
Satriano, N Baldini (ESB2005 – Sorrento, 11-15 Sept 2005)
31. Elevated serum activity of
tracp5b in osteosarcoma patients (OS) is associated with an
aggressive phenotype and with OS-induced osteoclast activity. S
Avnet, A Pellacani, A Longhi, F Perut, D Granchi, A Giunti, N
Baldini (Frontiers of skeletal biology - Davos, Switzerland, Mar 18
- 21 2006)
32. In vitro effects of
interferon-alpha on different cellular elements existing in a bone
metastasis of renal cell carcinoma. S Avnet, E Cenni, G Gancitano,
F Perut, D Granchi, ML Brandi, A Giunti, N Baldini (EORS annual
meeting – Bologna, 7-9 Jun 2006)
33. Elevated serum activity of
TRACP5b in osteosarcoma patients is associated with an aggressive
phenotype. M Cavaciocchi, S Avnet, A Pellacani, A Longhi, F Perut,
D Granchi, A Giunti, N Baldini (EORS annual meeting – Bologna, 7-9
Jun 2006)
34. Stromal cells derived from
giant cell tumor of bone show osteoblast-like features. M Salerno
M, S Avnet, A Pellacani, A Giunti, N Baldini (EORS annual meeting –
Bologna, 7-9 Jun 2006)
35. Stromal cells derived from
giant cell tumor of bone show an osteoblastic phenotype and
lack neoplastic features. M Salerno, S Avnet, A Pellacani, N Zini,
A Giunti, N Baldini (Connective Tissue Oncology Society Annual
Meeting - Venice, 2-4 Nov 2006)
36. Elevated serum tracp 5b levels
and outcome in osteosarcoma patients. S Avnet, A Pellacani, M
Salerno, A Longhi, D Granchi, M Cavaciocchi, A Giunti, N Baldini
(Connective Tissue Oncology Society Annual Meeting – Venice, 2-4
Nov 2006)
37. Biocompatibility of bone
targeted nanoparticles for intravenous administration. C Fotia, M
Salerno, E Cenni, D Granchi, S Avnet, F Castelli, D Micieli, MD
Sarpietro, R Pignatello, N Baldini (Pharmaceutical Nanothecnology
& drug delivery – Ferrara, 9 Mar 2007)
38. In Vitro Effect of
Platelet-Released Supernatant on Osteoclast Differentiation in Bone
Tissue Engineering. E Cenni, S. Avnet, M. Salerno, C. Fotia, D.
Granchi, A. Giunti, N. Baldini (21st European Conference on
Biomaterials, September 09-13th, 2007, Brighton, UK)
39. Blood Compatibility and
Cytocompatibility of Osteotropic Nanoparticles for Drug Delivery in
Bone Diseases. E Cenni, C. Fotia, M. Salerno, D. Granchi, S. Avnet,
F. Castelli, D. Micieli, M.G. Sarpietro, R. Pignatello, A. Giunti,
N. Baldini (21st European Conference on Biomaterials, September
09-13th, 2007, Brighton, UK)
40. In vitro antitumor effect of
bone-targeted nanoparticles loaded with doxorubicin. M Salerno C
Fotia, E Cenni, D Granchi, S Avnet, F Castelli, D Micieli, MD
Sampietro, R Pignatello N Baldini (VII meeting of molecular
oncology, Positano, may 14-17, 2007)
41. Biocompatibilità di
nanoparticelle osteotropiche a base di acido
poli(D,L-lattico-co-glicolico) e bifosnonato. M Salerno, C Fotia, E
Cenni, D Granchi, S Avnet, D Micieli, MG Sampietro, N Baldini
(congresso nazionale biomateriali, bologna 28-29 may 2007)
42. Antitumor effects of
bone-targeted nanoparticles loaded with doxorubicin on breast
cancer cell lines. M Salerno, C Fotia, E Cenni, D. Granchi, S
Avnet, F Castelli, D Micieli, MD Sampietro, R Pignatello, N Baldini
(MetaBre/BRECOSM Breast Cancer and Metastasis Conference, Roma, 5-7
Dec 2007)
43. Tumor-associated osteoclast
activity and aggressiveness of osteosarcoma. S Avnet, A Longhi, M
Salerno, J Halleen, F Perut, D Granchi, A Giunti, N Baldini. Bone
42 Supp 1: S91 (IBMS Davos workshop, Switzerland, Marzo 9-14,
2008)
44. Antineoplastic activity of
bone-targeted nanoparticles loaded with doxorubicin. M Salerno, S
Avnet, C Fotia, E Cenni, D Granchi, F Castelli, D Micieli, R
Pignatello, A Giunti. Bone 42 Suppl 1:S106( IBMS Davos workshop,
Switzerland, Marzo 9-14, 2008)
45. Osteotropic
poly(D,L-lactide-co-glycolide)-aòendronate nanoparticles for the
treatment of bone cancer. E Cenni, M Salerno, C Fotia, S Avnet, D
Granchi, F Castelli, D Micieli, R Pignatello, M Capulli, N Rucci, A
Teti, N Baldini. Cancer Treatment reviews 34 Supp 1:S74 (VII
International Meeting on Cancer Induced Bone Disease, Edimburgh, 28
Giugno – 2 Luglio, 2008)
46. Effects on bone-targeted
nanoparticles on bone metastasis. M Salerno, C. Fotia, S Avnet, E
Cenni, D Granchi, F Castelli, D Micieli, R Pignatello, N Rucci, A
Teti, A Giunti, N Baldini. Calcified Tissue International 82 Suppl
1: S91 (35th European Symposium on Calcified Tissues, Barcelona,
Maggio 24-28, 2008)
47. Doxorubicin-loaded
poly(D,L-lactide-co-glycolide)-alendronate nanoparticles for bone
cancer treatment: characterization and in vitro antineoplastic
activity. C Fotia, E Cenni, M Salerno, D Granchi, S Avnet, F
Castelli, D Miceli, MG Sarpietro, R Pignatello, N Baldini (8th
world biomaerials congress, Amsterdam, 28 maggio – 1 giugno
2008).
48. Doxorubicin-loaded osteotropic
nanoparticles for the treatment of skeletal metastases. M Salerno,
C Fotia, S Avnet, E Cenni, D Granchi, F Castelli, D Mceli, R
Pignatello, N Rucci, A Teti, N Baldini (X Congresso nazionale IORS
2008, Società Italiana in Ortopedia e TRaumatologia, Messina, 12-13
settembre 2008).
49. Biological Assessment of
Nanoparticles Made of a New Bone-Seeking Polymeric Conjugate for
Antitumour Drug Targeting. D. Micieli, M. Salerno, C. Fotia, E.
Cenni, D. Granchi, S. Avnet, M. G. Sarpietro, F. Castelli, and N.
Baldini, R. Pignatello. (36th Annual Meeting & Exposition of
the Controlled Release Society, 18-22 Luglio, Copenhagen,
Denmark).
50. Effetiveness pf psteotropic
nanoparticles on bone metastases. M. Salerno, C. Fotia, S. Avnet,
E. Cenni, D. Granchi, F. Castelli, D. Micieli, R. Pignatello, N.
Rucci, A. Teti, A. Giunti, N. Baldini. (The IX International
Meeting on Cancer Induced Bone Disease, 28-31 ottobre 2009).
51. The use of alizarin as a novel
therapeutic strategy in bone cancer treatment. Fotia C. Avnet S.
Baldini N (37th European Symposium on Calcified Tissues, 23-30 June
2010, Glasgow)
52. Alizarin, a tissue-specific
approach for bone treatment. Fotia C., Avnet S., Baldini N (The IX
International meeting on cancer induced bone disease, 28-31
october, 2009).
53. Serum levels od procollagen I
C-terminal extension peptide (PICP), cross-linked N-terminal
telopetide (NTx), and Active Tartrate-resistant acid phosphatase 5b
(TRACP 5b) in patients with hip prosthesis. F. Perut, L. Savarino,
S. Avnet, N. Baldini, A. Giunti (XII Italian Orthopaedic Research
Society, 7-8 May 2010, Pavia, Italy).
54. Proton dynamics in
musculoskeletal sarcomas. G. Di Pompo, S. Avnet, F. Perut, M.
Salerno, N. Baldini (19th EORS Meeting, 1-2 September 2011,
Vienna).
PRESENTAZIONI ORALI
1. Efficient expression of MET receptor in human
osteoblast by lentiviral vector transduction. S Avnet, S Patanè, N
Coltella, M Olivero, E Vigna, L Naldini, R Ferraccini, A Giunti, MF
Di Renzo, N Baldini. Bone, Supplement to Volume 30, Number 3, p
1s., 2001 (Frontiers of skeletal biology, ninth workshop on cell
biology of bone and cartilage in health and disease - Davos,
Switzerland, 16-19 Mar 2001)
2. Targeting met oncogene in human osteosarcoma by K-252
tyrosine-kinase inhibitor: a new therapeutic approach. S Avnet, F
Perut, R Ferracini, MF Di Renzo, N Baldini (CTOS Annual Meeting -
San Francisco, Nov 2002)
3. Study on the in vitro effect of platelet rich plasma on
bone endothelial cells and on osteoclast differentiation for
maxillo-facial surgery. S Avnet, E Cenni, D Granchi, F Perut, ML
Brandi, A Giunti, N Baldini (International meeting on modern
dentistry “Oral pathology, Stem cells, dental engineering -
Athens, 4-6 Nov 2005)
4. The serum level of TRACP 5b in osteosarcoma patients is
associated with an aggressive behaviour. Avnet S, Pellicani A,
Longhi A, Granchi D, Giunti A, Baldini N (53rd Orthopaedic Research
Society Annual meeting - San Diego, California, 11-14 Feb 2007)
